ProCE Banner Series

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL

Join us for an interactive live webinar featuring expert perspectives on treatment for patients with relapsed/refractory CLL. Choose 1 of 3 webinars, each with a different focus:

  • A CME/EBAC-certified roundtable webinar with physician faculty
  • An ANCC/AAPA-certified webinar with a focus on key information for nurses, NPs, and PAs
  • An ACPE-certified webinar focused on best practices for pharmacists

Be sure to bring your questions for the live Q&A session with the expert panel!

  AAPA
  | ACPE
  | AMA
  | ANCC
  | EBAC®
  | EBAC®
Who Should Attend

This program is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals globally who care for patients with chronic lymphocytic leukemia.

All Events

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL

Past Events

November

06

2024

6:00 PM - 7:30 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

ProCE Banner Faculty
Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Karen M. Fancher, PharmD, BCOP

Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist – Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

ProCE Banner Faculty
Nichole Fisher, RN, BSN

Clinical Research Supervisor
Willamette Valley Cancer Institute
Eugene, Oregon

ProCE Banner Faculty
Amy Goodrich, RN, MSN, CRNP-AC

Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

ProCE Banner Faculty
Josie Montegaard, MSN, AGPCNP-BC

Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Anthony J. Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

ProCE Banner Faculty
Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners' knowledge, competence, and performance to optimize clinical outcomes for patients with chronic lymphocytic leukemia.

Target Audience
This program is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals globally who care for patients with chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate new and emerging data on non-covalent BTK inhibitors into the management of patients with relapsed/refractory CLL/SLL

  • Plan therapeutic strategies for patients with relapsed/refractory CLL/SLL based on current guidelines, available clinical evidence, and expert recommendations

  • Proactively select and sequence treatment regimens and long-term treatment plans for individual patients with CLL/SLL to optimize clinical benefit

  • Assess patients with relapsed/refractory CLL/SLL who have progressed on or following covalent BTK inhibitor therapy for resistance mutations

  • Implement effective interprofessional team processes and workflows to promote adherence to and persistence with oral anticancer therapy to ensure optimal clinical outcomes in patients with relapsed/refractory CLL/SLL

  • Mitigate and manage treatment-related and disease-related adverse events in patients with relapsed/refractory CLL/SLL

Accreditation

October 30th, 2024 Event

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation 

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for up to 1.0 hours of external CE credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. 

The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC®. 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

Total effective education time: 90 mins 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


November 6, 2024 Event

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation. 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


November 13, 2024 Event

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-219-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Lilly.